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Mother-to-child transmission of hepatitis B virus in 
sub-Saharan Africa: time to act
What few people thought possible little more than a 
decade ago is now reality: scientiﬁ c and operational 
advances are greatly reducing the number of deaths 
from HIV. The number of infant infections has decreased 
by 58% between 2001 and 2013 and mother-to-child 
transmission (MTCT) of HIV might well be eliminated 
in the next few years.1 By contrast, the prevention and 
management of hepatitis B virus (HBV) infection lags 
well behind, at least in sub-Saharan Africa. 
The Global Burden of Disease Study2 highlighted the 
importance of chronic hepatitis B and its eﬀ ect on health, 
which is equivalent to that of tuberculosis or malaria. 
Worldwide about 240 million people have chronic 
hepatitis B. In sub-Saharan Africa more than 8% of the 
population are chronic carriers of HBV,3 the eﬀ ect of which 
is compounded by the high HIV prevalence. Hepatocellular 
carcinoma is the second most common cause of cancer 
in African men and third most common cause of cancer 
in African women, with more than 75% of cases being 
related to chronic hepatitis B, despite the availability of a 
safe and eﬀ ective vaccine for more than two decades. 
Early HBV transmission is the main route by which 
HBV infection is perpetuated in high-prevalence 
communities. About 90% of children infected through 
vertical transmission develop chronic hepatitis B. By 
contrast, 96% of adults will clear primary HBV infection. 
Therefore, interrupting early transmission is the key to 
breaking the cycle of ongoing HBV infection. 
Active immunisation is the cornerstone of preventing 
HBV MTCT. By 2012, 181 countries had implemented 
universal HBV vaccination, with global coverage 
estimated to be greater than 79%,3 leading to a 
remarkable reduction of chronic viral hepatitis B in high-
burden countries in east Asia.4 However, sub-Saharan 
Africa has a low infant HBV vaccine coverage: 72% in 
2012.5 Although the WHO recommends commencing 
HBV vaccination at birth,6 in much of Africa the ﬁ rst 
dose is given at about 6 weeks of age (the monovalent 
HBV vaccine superseded by the pentavalent vaccine 
DTP-HepB-Hib in many countries). This vaccination 
regimen is based on the observation that most African 
adult patients with chronic hepatitis B are of low 
infectivity and therefore have a low risk of transmitting 
perinatally. However, HBV infection in infants who 
were vaccinated according to this regimen is not 
uncommon,7,9 and studies suggest, although there is 
a clear regional variation, that up to 38% of pregnant 
African women with chronic hepatitis B are positive 
for hepatitis B e antigen (HBeAg) and therefore at 
high risk of transmitting HBV to their infants.7,8 To take 
full advantage of the beneﬁ ts of the HBV vaccine, its 
administration should start at birth. The addition of a 
birth dose to the current three-dose schedule has been 
shown to be cost-eﬀ ective in low-income countries.10 
Further, where HIV infection is prevalent, an additional 
dose of HBV vaccine in HIV-exposed babies could well be 
advantageous, since some data suggest poorer antibody 
responses in HIV-infected and HIV-exposed uninfected 
babies.11 The use of third-generation vaccines with 
additional viral epitopes (eg, pre-S domain), showing 
increased antigenicity, is a strategy that deserves 
investigation. 
In resource-rich settings, giving hepatitis B immuno-
globulin to infants born to mothers with high HBV 
viral loads, in addition to birth dose vaccine, is standard 
of care to prevent HBV MTCT. However, for most 
women in sub-Saharan countries, the cost and logistics 
of HBV diagnosis and administration of hepatitis B 
immunoglobulin are prohibitive. 
The administration of antiviral therapy from the 
second trimester of pregnancy will reduce maternal 
HBV viral load and decrease the risk of MTCT.12,13 The 
increased access to tenofovir for the treatment of HIV 
makes administration of this drug a feasible option 
for prevention of HBV MTCT. Although drugs such as 
lamivudine and telbivudine have been shown to reduce 
MTCT, tenofovir has a high barrier to resistance and has 
been used extensively in HIV-infected pregnant women. 
It has a good safety proﬁ le in pregnancy, although 
ongoing vigilance is needed.14 
Rapid immunochromatographic hepatitis B surface 
antigen (HBsAg) tests with acceptable performance are 
available to identify HBV-infected pregnant women. 
Cost-eﬀ ective point-of-care tests for combined HBsAg 
and HBeAg detection and determination of HBV viral 
load are in development. 
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How can these advances be implemented? Within the 
constraints of resource-poor settings and in view of their 
shared approaches, it seems eminently logical to harness 
the HIV prevention of MTCT infrastructure to address 
the problem of HBV MTCT. We suggest that identifying 
women at risk of HBV MTCT with a rapid test, starting 
and monitoring antiviral therapy in the late second or 
early third trimester, administering vaccine to the infant 
at birth, and contact tracing, are all within the expertise 
of HIV-trained health-care workers. Nevertheless these 
interventions will require additional resources.
Besides the increase in resources, other hurdles remain. 
Although tenofovir is available in many countries for 
HIV therapy, bureaucratic regulations and cost in many 
areas prevent access for HBV-monoinfected patients. 
HBV vaccine remains eﬃ  cacious when exposed to less 
stringent cold chains15 yet package inserts have not been 
modiﬁ ed to reﬂ ect these data. Additionally, the rollout 
of pentavalent vaccine might reduce accessibility to 
monovalent HBV vaccine.
The issue of HBV MTCT deserves our full attention. 
Screening women for HBV infection and starting 
antiviral therapy for those who need it, introducing HBV 
birth dose vaccine, and increasing overall coverage of 
vaccine are all feasible. What is needed now is strategic 
political and ﬁ nancial investment that could lead to 
the elimination of HBV MTCT in sub-Saharan Africa in 
our lifetime, and in so doing greatly reduce the global 
burden of this important public health problem.
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